Gene · 1292
COL6A2: collagen type VI alpha 2 chain
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. COL6A2: collagen type VI alpha 2 chain. Genes, record 1292. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1292
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P12110 | Collagen alpha-2(VI) chain | 1,019 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41880 | P12110 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4008 | P12110 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3588 | P12110 | Espacenet |
| EP 4641203 A2 | 2025-10-29 | 130 | P12110 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 3325 | P12110 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5962 | P12110 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5962 | P12110 | Espacenet |
| JP 2025517967 A | 2025-06-12 | 130 | P12110 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3588 | P12110 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4008 | P12110 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials66
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06169319 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT06151197 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT06065436 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05646602 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05254457 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT05152173 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT04874870 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT04680156 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT04496167 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2023-09-13 | ClinicalTrials.gov |
| NCT04236635 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2022-04-12 | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsNIH grants1,101
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | COL6A2 papers | Newest fiscal year |
|---|---|---|---|
| ZIANS003129 | Molecular and Clinical Manifestations of Matrix and Aggregate Myopathies | 28 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA062203 | Cancer Center Support Grant | 4 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30DK036836 | Diabetes Research Center | 3 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 3 | 2025 |
| P30ES023515 | Mount Sinai Center for Health and Environment Across the LifeSpan (HEALS) | 3 | 2025 |
| P30AR075043 | University of Michigan Skin Biology and Diseases Resource-based Center | 2 | 2025 |
1 to 10 of 1,101Source NIH's project files
See all 1,101 nih grantsPapers1,708
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-Cell RNA Sequencing of Uterine Tissue from a 70-Day-Old Female Rabbit: Cellular Composition and Fibroblast-Associated Networks. | Genes (Basel) | 2026 | 42793025 | PubTator, text mining | PubMed |
| Type VI collagen is proportionally lower around airways and blood vessels in idiopathic pulmonary fibrosis. | Am J Physiol Cell Physiol | 2026 | 42743047 | PubTator, text mining | PubMed |
| An Investigation to Study Morphology, Nanomechanical Attributes, Transcriptomics, and Proteomics of Tumor Associated Macrophages Derived Extracellular Vesicles in the Tumor Microenvironment. | J Anal Oncol | 2026 | 42719843 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing in Undiagnosed Muscular Dystrophies: A High Diagnostic Yield and Novel Insights From Iranian Families. | Hum Mutat | 2026 | 42553504 | PubTator, text mining | PubMed |
| Systems Biology and Experimental Validation Enable Discovery of MMP9-Centered Networks, Anticancer Activity, and Pharmacodynamic Signature in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | 42511800 | PubTator, text mining | PubMed |
| First- and Second-Trimester Cardiovascular Anomalies in Trisomy 21 Fetuses: Anatomy, Embryology, Genetics and Imaging. | J Pers Med | 2026 | 42506084 | PubTator, text mining | PubMed |
| Hypophosphatasia and collagen VI-related muscular dystrophy presenting with gait disturbance and recurrent fractures. | JCEM Case Rep | 2026 | 42395056 | PubTator, text mining | PubMed |
| Development of the cf-MMSP Assay for Enhanced Analytical Sensitivity of Methylated DNA in Breast Cancer Liquid Biopsy. | Cancer Epidemiol Biomarkers Prev | 2026 | 42334419 | PubTator, text mining | PubMed |
| Integrated bioinformatics, single-cell analysis, and experimental validation identify quercetin as a potential therapeutic candidate for intervertebral disc degeneration. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42329412 | PubTator, text mining | PubMed |
| Decoding regional keratinization in human oral mucosa through high-resolution spatial transcriptomics. | Sci Rep | 2026 | 42297861 | PubTator, text mining | PubMed |
1 to 10 of 1,708
See all 1,708 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1292
GET https://conductscience.org/api/genes/v1/1292/patents?page=2